LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lipid Profiling of Blood Samples Reveals Biomarkers for Cardiometabolic Disease Risk

By LabMedica International staff writers
Posted on 29 Apr 2022
Image: Lipidomics provides new biomarkers for cardiovascular disease and Type II diabetes (Photo courtesy of DIfE)
Image: Lipidomics provides new biomarkers for cardiovascular disease and Type II diabetes (Photo courtesy of DIfE)

A lipidomics-based analysis of plasma samples from a large cohort of participants identified several lipids associated with cardiometabolic disease risk that might serve as biomarkers for diagnosis of cardiovascular disease and Type II diabetes.

Lipidomics is the large-scale study of pathways and networks of cellular lipids in biological systems. The word "lipidome" is used to describe the complete lipid profile within a cell, tissue, organism, or ecosystem and is a subset of the "metabolome" which also includes the three other major classes of biological molecules: proteins/amino-acids, sugars, and nucleic acids. Lipidomics is a relatively recent research field that has been driven by rapid advances in technologies such as mass spectrometry (MS), nuclear magnetic resonance (NMR) spectroscopy, fluorescence spectroscopy, dual polarization interferometry, and computational methods coupled with the recognition of the role of lipids in many metabolic diseases such as obesity, atherosclerosis, stroke, hypertension, and diabetes.

Cardiovascular disease is the leading cause of death worldwide, accounting for around 18 million deaths per year. People with Type II diabetes have a two- to threefold increased risk of suffering a heart attack or stroke. Accordingly, there is a great need to identify biomarkers that can indicate the development of disease at an early stage in order to prevent or at least mitigate its onset.

In this regard, investigators at the German Institute of Human Nutrition (DifE) of the German Center for Diabetes Research (Deutsches Zentrum fuer Diabetesforschung) evaluated the fatty acid profiles in 2,414 blood samples from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. The samples were collected as early as the 1990s and in part came from participants who developed cardiovascular disease or Type II diabetes in subsequent years.

Using high-throughput lipidomics, the investigators identified a total of 282 different lipids, 69 of which were associated with at least one of the two diseases. Several monoacylglycerols and 16 and 18 chain fatty acids in diacylglycerols were associated with both outcomes. Cholesteryl esters, free fatty acids, and sphingolipids were largely cardiovascular disease-specific, while several (glycero)phospholipids were Type II diabetes-specific.

First author Dr. Fabian Eichelmann, a researcher in the department of molecular epidemiology at the German Institute of Human Nutrition and at the German Center for Diabetes Research, said, "A statistical association with cardiovascular diseases was found for 49 lipids, which mainly belonged to the cholesterol esters and sphingolipids. Twelve lipids were associated with Type II diabetes, the majority of which were glycerol and phospholipids. An association with both diseases was seen for eight lipids, among which several monoacylglycerides stood out."

The study was published in the April 15, 2022, online edition of the journal Circulation.

Related Links:
German Institute of Human Nutrition 
German Center for Diabetes Research 

 

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Silver Member
PCR Plates
Diamond Shell PCR Plates

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more